A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs INCMGA 0012 (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms POD1UM-201
- Sponsors Incyte Corporation
- 21 Sep 2018 Status changed from not yet recruiting to recruiting.
- 07 Aug 2018 According to MacroGenics media release, data from this study is anticipated in 2020-2021.
- 02 Aug 2018 New trial record